Skip to main content
Top
Gepubliceerd in: Quality of Life Research 4/2016

01-04-2016

Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms

Auteurs: Brett Doble, Paula Lorgelly

Gepubliceerd in: Quality of Life Research | Uitgave 4/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Abstract

Purpose

To determine the external validity of existing mapping algorithms for predicting EQ-5D-3L utility values from EORTC QLQ-C30 responses and to establish their generalizability in different types of cancer.

Methods

A main analysis (pooled) sample of 3560 observations (1727 patients) and two disease severity patient samples (496 and 93 patients) with repeated observations over time from Cancer 2015 were used to validate the existing algorithms. Errors were calculated between observed and predicted EQ-5D-3L utility values using a single pooled sample and ten pooled tumour type-specific samples. Predictive accuracy was assessed using mean absolute error (MAE) and standardized root-mean-squared error (RMSE). The association between observed and predicted EQ-5D utility values and other covariates across the distribution was tested using quantile regression. Quality-adjusted life years (QALYs) were calculated using observed and predicted values to test responsiveness.

Results

Ten ‘preferred’ mapping algorithms were identified. Two algorithms estimated via response mapping and ordinary least-squares regression using dummy variables performed well on number of validation criteria, including accurate prediction of the best and worst QLQ-C30 health states, predicted values within the EQ-5D tariff range, relatively small MAEs and RMSEs, and minimal differences between estimated QALYs. Comparison of predictive accuracy across ten tumour type-specific samples highlighted that algorithms are relatively insensitive to grouping by tumour type and affected more by differences in disease severity.

Conclusions

Two of the ‘preferred’ mapping algorithms suggest more accurate predictions, but limitations exist. We recommend extensive scenario analyses if mapped utilities are used in cost-utility analyses.
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Voetnoten
1
More recently, the EQ-5D-5L has been developed to improve the instrument’s sensitivity and reduce ceiling effects commonly observed when using the EQ-5D-3L [7]. This version of the EQ-5D has five levels for each item (no problems, slight problems, moderate problems, severe problems, and extreme problems). To date, no research has mapped a non-preference-based instrument to the EQ-5D-5L.
 
2
There are several versions of the QLQ-C30 questionnaire: the current version 3 differs from version 1; in that, it has four-point scales for the Physical and Role Functioning items (items 1–7) instead of two-point scales [1]. Version 2 differs from version 3 only in the number of scale points in the Physical Functioning items (items 1–5) [27].
 
3
The cohort protocol stated that patients were to be followed up at 6, 12, and 24 months after enrolment, and every 12 months thereafter; however, advanced cancer (more severe) patients were fast-tracked with an early follow-up at 3 months in addition to the time points above. The follow-up time points are adhered to ± month, where practically possible.
 
4
For items 1–5 in the Cancer 2015, dataset responses greater than or equal to 3 were assumed to be ‘Yes’ and responses less than or equal to 2 were assumed to be ‘No’.
 
5
These tariffs each result in different theoretical ranges of utility values between 1 (full health) and some lower value equal to a negative number (worse than dead), where a value of zero represents dead (e.g. UK tariff has a theoretical range of −0.594 to 1).
 
6
Standardized by dividing RMSE by the maximal tariff EQ-5D range (e.g. for UK ((1.594) × 100); minimum values: UK = −0.594, US = −0.104, NL = −0.329, KR = −0.171.
 
Literatuur
1.
go back to reference Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365–376.CrossRefPubMed
2.
go back to reference Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.PubMed Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The functional assessment of cancer therapy scale: Development and validation of the general measure. Journal of Clinical Oncology, 11(3), 570–579.PubMed
4.
go back to reference Brazier, J. E., & Roberts, J. (2004). The estimation of a preference-based measure of health from the SF-12. Medical Care, 42(9), 851–859.CrossRefPubMed Brazier, J. E., & Roberts, J. (2004). The estimation of a preference-based measure of health from the SF-12. Medical Care, 42(9), 851–859.CrossRefPubMed
5.
go back to reference Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.CrossRefPubMed Feeny, D., Furlong, W., Torrance, G. W., Goldsmith, C. H., Zhu, Z., DePauw, S., et al. (2002). Multiattribute and single-attribute utility functions for the health utilities index mark 3 system. Medical Care, 40(2), 113–128.CrossRefPubMed
6.
go back to reference Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care, 11(2), 215–225.CrossRefPubMed Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2010). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics: HEPAC: Health Economics in Prevention and Care, 11(2), 215–225.CrossRefPubMed
7.
go back to reference Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedPubMedCentral Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., et al. (2011). Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research, 20(10), 1727–1736.CrossRefPubMedPubMedCentral
8.
go back to reference McKenzie, L., & van der Pol, M. (2009). Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: The potential to estimate QALYs without generic preference data. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12(1), 167–171.CrossRef McKenzie, L., & van der Pol, M. (2009). Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: The potential to estimate QALYs without generic preference data. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12(1), 167–171.CrossRef
9.
go back to reference Kontodimopoulos, N., Aletras, V. H., Paliouras, D., & Niakas, D. (2009). Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12(8), 1151–1157.CrossRef Kontodimopoulos, N., Aletras, V. H., Paliouras, D., & Niakas, D. (2009). Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12(8), 1151–1157.CrossRef
10.
go back to reference Jang, R. W., Isogai, P. K., Mittmann, N., Bradbury, P. A., Shepherd, F. A., Feld, R., & Leighl, N. B. (2010). Derivation of utility values from European Organization for research and treatment of cancer quality of life-core 30 questionnaire values in lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 5(12), 1953–1957.CrossRef Jang, R. W., Isogai, P. K., Mittmann, N., Bradbury, P. A., Shepherd, F. A., Feld, R., & Leighl, N. B. (2010). Derivation of utility values from European Organization for research and treatment of cancer quality of life-core 30 questionnaire values in lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 5(12), 1953–1957.CrossRef
11.
go back to reference Crott, R., & Briggs, A. (2010). Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. The European Journal of Health Economics : HEPAC: Health Economics in Prevention and Care, 11(4), 427–434.CrossRefPubMed Crott, R., & Briggs, A. (2010). Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. The European Journal of Health Economics : HEPAC: Health Economics in Prevention and Care, 11(4), 427–434.CrossRefPubMed
12.
go back to reference Versteegh, M. M., Rowen, D., Brazier, J. E., & Stolk, E. A. (2010). Mapping onto Eq-5 D for patients in poor health. Health and Quality of Life Outcomes, 8, 141.CrossRefPubMedPubMedCentral Versteegh, M. M., Rowen, D., Brazier, J. E., & Stolk, E. A. (2010). Mapping onto Eq-5 D for patients in poor health. Health and Quality of Life Outcomes, 8, 141.CrossRefPubMedPubMedCentral
13.
go back to reference Kim, E. J., Ko, S. K., & Kang, H. Y. (2012). Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 21(7), 1193–1203.CrossRef Kim, E. J., Ko, S. K., & Kang, H. Y. (2012). Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 21(7), 1193–1203.CrossRef
14.
go back to reference Versteegh, M. M., Leunis, A., Luime, J. J., Boggild, M., Uyl-de Groot, C. A., & Stolk, E. A. (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making: An International Journal of the Society for Medical Decision Making, 32(4), 554–568.CrossRef Versteegh, M. M., Leunis, A., Luime, J. J., Boggild, M., Uyl-de Groot, C. A., & Stolk, E. A. (2012). Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D. Medical Decision Making: An International Journal of the Society for Medical Decision Making, 32(4), 554–568.CrossRef
15.
go back to reference Kim, S. H., Jo, M. W., Kim, H. J., & Ahn, J. H. (2012). Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health and Quality of Life Outcomes, 10, 151.CrossRefPubMedPubMedCentral Kim, S. H., Jo, M. W., Kim, H. J., & Ahn, J. H. (2012). Mapping EORTC QLQ-C30 onto EQ-5D for the assessment of cancer patients. Health and Quality of Life Outcomes, 10, 151.CrossRefPubMedPubMedCentral
16.
go back to reference Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1–224.CrossRefPubMedPubMedCentral Longworth, L., Yang, Y., Young, T., Mulhern, B., Hernandez Alava, M., Mukuria, C., et al. (2014). Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment, 18(9), 1–224.CrossRefPubMedPubMedCentral
17.
go back to reference Proskorovsky, I., Lewis, P., Williams, C. D., Jordan, K., Kyriakou, C., Ishak, J., & Davies, F. E. (2014). Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health and Quality of Life Outcomes, 12(1), 35.CrossRefPubMedPubMedCentral Proskorovsky, I., Lewis, P., Williams, C. D., Jordan, K., Kyriakou, C., Ishak, J., & Davies, F. E. (2014). Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. Health and Quality of Life Outcomes, 12(1), 35.CrossRefPubMedPubMedCentral
18.
go back to reference Crott, R., Versteegh, M., & Uyl-de-Groot, C. (2013). An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 22(5), 1045–1054.CrossRef Crott, R., Versteegh, M., & Uyl-de-Groot, C. (2013). An assessment of the external validity of mapping QLQ-C30 to EQ-5D preferences. Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation, 22(5), 1045–1054.CrossRef
19.
go back to reference Rowen, D., Young, T., Brazier, J., & Gaugris, S. (2012). Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 15(8), 1059–1068.CrossRef Rowen, D., Young, T., Brazier, J., & Gaugris, S. (2012). Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 15(8), 1059–1068.CrossRef
20.
go back to reference Crott, R. (2014). Mapping algorithms from QLQ-C30 to EQ-5D utilities: No firm ground to stand on yet. Expert Review of Pharmacoecon and Outcomes Research, 14(4), 569–576.CrossRef Crott, R. (2014). Mapping algorithms from QLQ-C30 to EQ-5D utilities: No firm ground to stand on yet. Expert Review of Pharmacoecon and Outcomes Research, 14(4), 569–576.CrossRef
21.
go back to reference Arnold, D. T., Rowen, D., Versteegh, M. M., Morley, A., Hooper, C. E., & Maskell, N. A. (2015). Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health and Quality of Life Outcomes, 13, 6.CrossRefPubMedPubMedCentral Arnold, D. T., Rowen, D., Versteegh, M. M., Morley, A., Hooper, C. E., & Maskell, N. A. (2015). Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma. Health and Quality of Life Outcomes, 13, 6.CrossRefPubMedPubMedCentral
22.
go back to reference Altman, D. G., & Royston, P. (2000). What do we mean by validating a prognostic model? Statistics in Medicine, 19(4), 453–473.CrossRefPubMed Altman, D. G., & Royston, P. (2000). What do we mean by validating a prognostic model? Statistics in Medicine, 19(4), 453–473.CrossRefPubMed
23.
go back to reference Justice, A. C., Covinsky, K. E., & Berlin, J. A. (1999). Assessing the generalizability of prognostic information. Annals of Internal Medicine, 130(6), 515–524.CrossRefPubMed Justice, A. C., Covinsky, K. E., & Berlin, J. A. (1999). Assessing the generalizability of prognostic information. Annals of Internal Medicine, 130(6), 515–524.CrossRefPubMed
24.
go back to reference Steyerberg, E. W., Bleeker, S. E., Moll, H. A., Grobbee, D. E., & Moons, K. G. M. (2003). Internal and external validation of predictive models: A simulation study of bias and precision in small samples. Journal of Clinical Epidemiology, 56(5), 441–447.CrossRefPubMed Steyerberg, E. W., Bleeker, S. E., Moll, H. A., Grobbee, D. E., & Moons, K. G. M. (2003). Internal and external validation of predictive models: A simulation study of bias and precision in small samples. Journal of Clinical Epidemiology, 56(5), 441–447.CrossRefPubMed
25.
go back to reference Dakin, H. (2013). Review of studies mapping from quality of life or clinical measures to EQ-5D: An online database. Health and Quality of Life Outcomes, 11(1), 151.CrossRefPubMedPubMedCentral Dakin, H. (2013). Review of studies mapping from quality of life or clinical measures to EQ-5D: An online database. Health and Quality of Life Outcomes, 11(1), 151.CrossRefPubMedPubMedCentral
26.
go back to reference Wong, S. Q., Fellowes, A., Doig, K., Ellul, J., Bosma, T. J., Irwin, D., et al. (2015). Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. British Journal of Cancer, 112(8), 1411–1420.CrossRefPubMed Wong, S. Q., Fellowes, A., Doig, K., Ellul, J., Bosma, T. J., Irwin, D., et al. (2015). Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. British Journal of Cancer, 112(8), 1411–1420.CrossRefPubMed
27.
go back to reference Osoba, D., Aaronson, N., Zee, B., Sprangers, M., & te Velde, A. (1997). Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The study group on quality of life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Quality of Life Research, 6(2), 103–108.CrossRefPubMed Osoba, D., Aaronson, N., Zee, B., Sprangers, M., & te Velde, A. (1997). Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The study group on quality of life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Quality of Life Research, 6(2), 103–108.CrossRefPubMed
28.
go back to reference EORTC. (2001). EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussels: EORTC. EORTC. (2001). EORTC QLQ-C30 Scoring Manual (3rd ed.). Brussels: EORTC.
29.
go back to reference Xie, F., Gaebel, K., Perampaladas, K., Doble, B., & Pullenayegum, E. (2014). Comparing EQ-5D valuation studies: A systematic review and methodological reporting checklist. Medical Decision Making, 34(1), 8–20.CrossRefPubMed Xie, F., Gaebel, K., Perampaladas, K., Doble, B., & Pullenayegum, E. (2014). Comparing EQ-5D valuation studies: A systematic review and methodological reporting checklist. Medical Decision Making, 34(1), 8–20.CrossRefPubMed
30.
go back to reference Longworth, L., & Rowen, D. (2013). Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(1), 202–210.CrossRef Longworth, L., & Rowen, D. (2013). Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 16(1), 202–210.CrossRef
31.
32.
go back to reference San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., et al. (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359(9), 906–917.CrossRefPubMed San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., et al. (2008). Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359(9), 906–917.CrossRefPubMed
33.
go back to reference Huang, I. C., Willke, R. J., Atkinson, M. J., Lenderking, W. R., Frangakis, C., & Wu, A. W. (2007). US and UK versions of the EQ-5D preference weights: Does choice of preference weights make a difference? Quality of Life Research, 16(6), 1065–1072.CrossRefPubMed Huang, I. C., Willke, R. J., Atkinson, M. J., Lenderking, W. R., Frangakis, C., & Wu, A. W. (2007). US and UK versions of the EQ-5D preference weights: Does choice of preference weights make a difference? Quality of Life Research, 16(6), 1065–1072.CrossRefPubMed
34.
go back to reference Pennington, B., & Davis, S. (2014). Mapping from the Health Assessment Questionnaire to the EQ-5D: The impact of different algorithms on cost-effectiveness results. Value in health, 17(8): 762–771. Pennington, B., & Davis, S. (2014). Mapping from the Health Assessment Questionnaire to the EQ-5D: The impact of different algorithms on cost-effectiveness results. Value in health, 17(8): 762–771.
35.
go back to reference Chan, K. K., Willan, A. R., Gupta, M., & Pullenayegum, E. (2014). Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: Statistical explanations and potential remedies. Medical Decision Making, 34(7), 863–872.CrossRefPubMed Chan, K. K., Willan, A. R., Gupta, M., & Pullenayegum, E. (2014). Underestimation of uncertainties in health utilities derived from mapping algorithms involving health-related quality-of-life measures: Statistical explanations and potential remedies. Medical Decision Making, 34(7), 863–872.CrossRefPubMed
36.
go back to reference Fayers, P. M., & Hays, R. D. (2014). Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health, 17(2), 261–265.CrossRefPubMedPubMedCentral Fayers, P. M., & Hays, R. D. (2014). Should linking replace regression when mapping from profile-based measures to preference-based measures? Value Health, 17(2), 261–265.CrossRefPubMedPubMedCentral
37.
go back to reference Lu, G., Brazier, J. E., & Ades, A. E. (2013). Mapping from disease-specific to generic health-related quality-of-life scales: A common factor model. Value Health, 16(1), 177–184.CrossRefPubMed Lu, G., Brazier, J. E., & Ades, A. E. (2013). Mapping from disease-specific to generic health-related quality-of-life scales: A common factor model. Value Health, 16(1), 177–184.CrossRefPubMed
38.
go back to reference Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., & Gray, A. (2015). Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement, Quality of Life Research. Petrou, S., Rivero-Arias, O., Dakin, H., Longworth, L., Oppe, M., Froud, R., & Gray, A. (2015). Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement, Quality of Life Research.
39.
go back to reference McCabe, C., Edlin, R., Meads, D., Brown, C., & Kharroubi, S. (2013). Constructing indirect utility models: Some observations on the principles and practice of mapping to obtain health state utilities. Pharmacoeconomics, 31(8), 635–641.CrossRefPubMed McCabe, C., Edlin, R., Meads, D., Brown, C., & Kharroubi, S. (2013). Constructing indirect utility models: Some observations on the principles and practice of mapping to obtain health state utilities. Pharmacoeconomics, 31(8), 635–641.CrossRefPubMed
40.
go back to reference Xie, F., Pickard, A. S., Krabbe, P. F., Revicki, D., Viney, R., Devlin, N., & Feeny, D. (2015). A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE). Pharmacoeconomics, 33(8), 867–877.CrossRefPubMedPubMedCentral Xie, F., Pickard, A. S., Krabbe, P. F., Revicki, D., Viney, R., Devlin, N., & Feeny, D. (2015). A checklist for reporting valuation studies of multi-attribute utility-based instruments (CREATE). Pharmacoeconomics, 33(8), 867–877.CrossRefPubMedPubMedCentral
41.
go back to reference Shenfine, J., McNamee, P., Steen, N., Bond, J., & Griffin, S. M. (2005). A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technology Assessment (Winchester, England), 9(5): 3. Shenfine, J., McNamee, P., Steen, N., Bond, J., & Griffin, S. M. (2005). A pragmatic randomised controlled trial of the cost-effectiveness of palliative therapies for patients with inoperable oesophageal cancer. Health Technology Assessment (Winchester, England), 9(5): 3.
42.
go back to reference Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed Dolan, P. (1997). Modeling valuations for EuroQol health states. Medical Care, 35(11), 1095–1108.CrossRefPubMed
43.
go back to reference Prescott, R. J., Kunkler, I. H., Williams, L. J., King, C. C., Jack, W., van der Pol, M., et al. (2007). A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technology Assessment (Winchester, England), 11(31):1–149. Prescott, R. J., Kunkler, I. H., Williams, L. J., King, C. C., Jack, W., van der Pol, M., et al. (2007). A randomised controlled trial of postoperative radiotherapy following breast-conserving surgery in a minimum-risk older population. The PRIME trial. Health Technology Assessment (Winchester, England), 11(31):1–149.
44.
go back to reference Dolan, P., Gudex, C., Kind, P., & Williams, A. (1996). The time trade-off method: Results from a general population study. Health Economics, 5(2), 141–154.CrossRefPubMed Dolan, P., Gudex, C., Kind, P., & Williams, A. (1996). The time trade-off method: Results from a general population study. Health Economics, 5(2), 141–154.CrossRefPubMed
45.
go back to reference Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.CrossRefPubMed Shaw, J. W., Johnson, J. A., & Coons, S. J. (2005). US valuation of the EQ-5D health states: Development and testing of the D1 valuation model. Medical Care, 43(3), 203–220.CrossRefPubMed
46.
go back to reference Therasse, P., Mauriac, L., Welnicka-Jaskiewicz, M., Bruning, P., Cufer, T., Bonnefoi, H., et al. (2003). Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. Journal of Clinical Oncology, 21(5), 843–850.CrossRefPubMed Therasse, P., Mauriac, L., Welnicka-Jaskiewicz, M., Bruning, P., Cufer, T., Bonnefoi, H., et al. (2003). Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. Journal of Clinical Oncology, 21(5), 843–850.CrossRefPubMed
47.
go back to reference Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E., et al. (2003). Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood, 101(6), 2144–2151.CrossRefPubMed Segeren, C. M., Sonneveld, P., van der Holt, B., Vellenga, E., Croockewit, A. J., Verhoef, G. E., et al. (2003). Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: A prospective randomized phase 3 study. Blood, 101(6), 2144–2151.CrossRefPubMed
48.
go back to reference Lamers, L. M., McDonnell, J., Stalmeier, P. F., Krabbe, P. F., & Busschbach, J. J. (2006). The Dutch tariff: Results and arguments for an effective design for national EQ-5D valuation studies. Health Economics, 15(10), 1121–1132.CrossRefPubMed Lamers, L. M., McDonnell, J., Stalmeier, P. F., Krabbe, P. F., & Busschbach, J. J. (2006). The Dutch tariff: Results and arguments for an effective design for national EQ-5D valuation studies. Health Economics, 15(10), 1121–1132.CrossRefPubMed
49.
go back to reference Doorduijn, J. K., van der Holt, B., van Imhoff, G. W., van der Hem, K. G., Kramer, M. H., van Oers, M. H., et al. (2003). CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 21(16), 3041–3050.CrossRefPubMed Doorduijn, J. K., van der Holt, B., van Imhoff, G. W., van der Hem, K. G., Kramer, M. H., van Oers, M. H., et al. (2003). CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 21(16), 3041–3050.CrossRefPubMed
50.
go back to reference Lee, Y. K., Nam, H. S., Chuang, L. H., Kim, K. Y., Yang, H. K., Kwon, I. S., et al. (2009). South Korean time trade-off values for EQ-5D health states: Modeling with observed values for 101 health states. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12(8), 1187–1193.CrossRef Lee, Y. K., Nam, H. S., Chuang, L. H., Kim, K. Y., Yang, H. K., Kwon, I. S., et al. (2009). South Korean time trade-off values for EQ-5D health states: Modeling with observed values for 101 health states. Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, 12(8), 1187–1193.CrossRef
51.
go back to reference Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.CrossRefPubMed Kim, S. H., Kim, H. J., Lee, S. I., & Jo, M. W. (2012). Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea. Quality of Life Research, 21(6), 1065–1073.CrossRefPubMed
52.
go back to reference Kim, S. H., Hwang, J. S., Kim, T. W., Hong, Y. S., & Jo, M. W. (2012). Validity and reliability of the EQ-5D for cancer patients in Korea. Supportive Care in Cancer, 20(12), 3155–3160.CrossRefPubMed Kim, S. H., Hwang, J. S., Kim, T. W., Hong, Y. S., & Jo, M. W. (2012). Validity and reliability of the EQ-5D for cancer patients in Korea. Supportive Care in Cancer, 20(12), 3155–3160.CrossRefPubMed
53.
go back to reference Jordan, K., Proskorovsky, I., Lewis, P., Ishak, J., Payne, K., Lordan, N., et al. (2014). Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: Results of a European, multicenter cohort study. Supportive Care in Cancer, 22(2), 417–426.CrossRefPubMedPubMedCentral Jordan, K., Proskorovsky, I., Lewis, P., Ishak, J., Payne, K., Lordan, N., et al. (2014). Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: Results of a European, multicenter cohort study. Supportive Care in Cancer, 22(2), 417–426.CrossRefPubMedPubMedCentral
Metagegevens
Titel
Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms
Auteurs
Brett Doble
Paula Lorgelly
Publicatiedatum
01-04-2016
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 4/2016
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-015-1116-2

Andere artikelen Uitgave 4/2016

Quality of Life Research 4/2016 Naar de uitgave